These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37537424)

  • 1. Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption.
    Alimpertis N; Tsekouras AA; Macheras P
    Pharm Res; 2023 Sep; 40(9):2167-2175. PubMed ID: 37537424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations.
    Chryssafidis P; Tsekouras AA; Macheras P
    Pharm Res; 2021 Aug; 38(8):1345-1356. PubMed ID: 34341958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models.
    Chryssafidis P; Tsekouras AA; Macheras P
    Pharm Res; 2022 Apr; 39(4):691-701. PubMed ID: 35378697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the Finite Absorption Time (F.A.T.) Concept in the Assessment of Bioequivalence.
    Tsekouras AA; Macheras P
    Pharm Res; 2024 Jul; 41(7):1413-1425. PubMed ID: 38898304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based Pharmacokinetic Models under the Prism of the Finite Absorption Time Concept.
    Wu D; Tsekouras AA; Macheras P; Kesisoglou F
    Pharm Res; 2023 Feb; 40(2):419-429. PubMed ID: 36050545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Columbus' egg: Oral drugs are absorbed in finite time.
    Macheras P; Tsekouras AA
    Eur J Pharm Sci; 2022 Sep; 176():106265. PubMed ID: 35863551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The area function method for assessing the drug absorption rate in linear systems with zero-order input.
    Cheng H; Jusko WJ
    Pharm Res; 1989 Feb; 6(2):133-9. PubMed ID: 2762213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development-Industry Case Studies.
    Kesisoglou F; Chung J; van Asperen J; Heimbach T
    J Pharm Sci; 2016 Sep; 105(9):2723-2734. PubMed ID: 26886317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revising Pharmacokinetics of Oral Drug Absorption: I Models Based on Biopharmaceutical/Physiological and Finite Absorption Time Concepts.
    Macheras P; Chryssafidis P
    Pharm Res; 2020 Sep; 37(10):187. PubMed ID: 32888087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five modified numerical deconvolution methods for biopharmaceutics and pharmacokinetics studies.
    Yu Z; Schwartz JB; Sugita ET; Foehl HC
    Biopharm Drug Dispos; 1996 Aug; 17(6):521-40. PubMed ID: 8866043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IVIVC Revised.
    Alimpertis N; Simitopoulos A; Tsekouras AA; Macheras P
    Pharm Res; 2024 Feb; 41(2):235-246. PubMed ID: 38191705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.
    Anand O; Pepin XJH; Kolhatkar V; Seo P
    Pharm Res; 2022 Aug; 39(8):1681-1700. PubMed ID: 35585448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of absorption rate constant (ka) following oral administration by Wagner-Nelson, Loo-Riegelman, and statistical moments in the presence of a secondary peak.
    Mahmood I
    Drug Metabol Drug Interact; 2004; 20(1-2):85-100. PubMed ID: 15283305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.
    Ameijeiras Rodríguez C; Henriques SC; Sancho-Araiz A; Trocóniz IF; Almeida L; Silva NE
    Pharm Res; 2021 Dec; 38(12):2047-2063. PubMed ID: 34932170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Provisional No-Effect Threshold of Sugar Alcohols on Oral Drug Absorption Estimated by Physiologically Based Biopharmaceutics Model.
    Yamane M; Matsui K; Sugihara M; Tokunaga Y
    J Pharm Sci; 2021 Jan; 110(1):467-477. PubMed ID: 32470348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.
    Darwich AS; Margolskee A; Pepin X; Aarons L; Galetin A; Rostami-Hodjegan A; Carlert S; Hammarberg M; Hilgendorf C; Johansson P; Karlsson E; Murphy D; Tannergren C; Thörn H; Yasin M; Mazuir F; Nicolas O; Ramusovic S; Xu C; Pathak SM; Korjamo T; Laru J; Malkki J; Pappinen S; Tuunainen J; Dressman J; Hansmann S; Kostewicz E; He H; Heimbach T; Wu F; Hoft C; Pang Y; Bolger MB; Huehn E; Lukacova V; Mullin JM; Szeto KX; Costales C; Lin J; McAllister M; Modi S; Rotter C; Varma M; Wong M; Mitra A; Bevernage J; Biewenga J; Van Peer A; Lloyd R; Shardlow C; Langguth P; Mishenzon I; Nguyen MA; Brown J; Lennernäs H; Abrahamsson B
    Eur J Pharm Sci; 2017 Jan; 96():626-642. PubMed ID: 27693299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
    O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
    J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.